PART 4 SUMMARY OF EVIDENCE – Provide an overview of all key journal articles or research published in the public domain related to the proposed service that is for your application (limiting these to the English language only). Please do not attach full text articles, this is just intended to be a summary. Type of Title of journal article Short description of Website link to journal article or research (if available) Date of study or research project research (max 50 design* (including any words)** * identifier or study lead if relevant) 1. Randomised, Cardoso et al (2016) MINDACT is a trial of http://www.nejm.org/doi/full/10.1056/NEJMoa1602253 August 25, MINDACT Trial. 6,693 early stage breast 2016. prospective (Microarray In Node cancer patients across randomised negative and 1-3 lymph 112 centers in Europe. It trial. node positive Disease is a prospective may Avoid randomized trial proving ChemoTherapy Trial) the clinical utility of the 70 gene assay, in 70-Gene Signature as helping to predict an Aid to Treatment patient outcomes and Decisions in Early-Stage response to Breast Cancer. chemotherapy. 2. Editorial Increasing Precision in Editorial published in http://www.nejm.org/doi/full/10.1056/NEJMe1607947 August 25, Adjuvant Therapy for NEJM authored by Hudis 2016. Breast Cancer. and Dickler. Concluded that the above MINDACT study allows clinicians to consider ordering MammaPrint for chemotherapy patients who wish to avoid it should they be genomically low-risk.
PART 4 – SUMMARY OF EVIDENCE Provide an overview of all key journal articles or research published in the public domain related to the proposed service that is for your application (limiting these to the English language only). Please do not attach full text articles, this is just intended to be a summary. Type of study design* Title of journal article or research project (including any identifier or study lead if relevant) Short description of research (max 50 words)** Website link to journal article or research (if available) Date of 1. Randomised, prospective randomised trial. Cardoso et al (2016) MINDACT Trial. (Microarray In Node negative and 1-3 lymph node positive Disease may Avoid ChemoTherapy Trial) 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. MINDACT is a trial of 6,693 early stage breast cancer patients across 112 centers in Europe. It is a prospective randomized trial proving the clinical utility of the 70 gene assay, in helping to predict patient outcomes and response to chemotherapy. http://www.nejm.org/doi/full/10.1056/NEJMoa1602253 August 25, 2016. 2. Editorial Increasing Precision in Adjuvant Therapy for Breast Cancer. Editorial published in NEJM authored by Hudis and Dickler. Concluded that the above MINDACT study allows clinicians to consider ordering MammaPrint for chemotherapy patients who wish to avoid it should they be genomically low-risk. http://www.nejm.org/doi/full/10.1056/NEJMe1607947 August 25, 2016. *